Antibodies that specifically bind to MUC-1 and uses thereof

By developing chimeric and humanized antibodies and combining anti-CD3 antibodies to form bispecific antibodies, the existing anti-MUC1 antibodies have limited effects and major side effects in treating cancer, and significantly improve the therapeutic effect and safety of antibodies sex.

CN119095878APending Publication Date: 2024-12-06CYRON THERAPEUTICS CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280093062.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2022-01-24
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing anti-MUC1 antibodies have limited effectiveness in treating cancer, and animal-derived antibodies trigger immune rejection, resulting in side effects, and improved antibodies need to be developed to improve therapeutic effects and reduce side effects.

Method used

Chimeric antibodies and humanized antibodies were developed to improve antigen binding efficiency by modifying the CDR region and hinge region, and to form bispecific antibodies in combination with anti-CD3 antibodies to enhance the recognition and attack ability of cancer cells.

Benefits of technology

It improves the antigen binding efficiency and cancer cell killing ability of the antibody, reduces the immune rejection reaction, and significantly improves the therapeutic effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119095878A_ABST
    Figure CN119095878A_ABST
Patent Text Reader

Abstract

Provided are an anti-MUC1 antibody, an anti-MUC1 / anti-CD3 bispecific antibody, and a pharmaceutical composition comprising the same, for use in the prevention and / or treatment of cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] Provided are anti-MUC1 antibodies, anti-MUC1 / anti-CD3 bispecific antibodies and pharmaceutical compositions containing the same for preventing and / or treating cancer. Background Art

[0002] MUC1 (mucin-1) is a mucin glycoprotein and is a transmembrane glycoprotein containing multiple glycosylated extracellular domains. The length of MUC1 on the cell surface is 200nm to 500nm, and MUC1 is located in the apical membrane of normal epithelial cells. MUC1 is expressed in glandular or luminal epithelial cells of many organs such as breast, stomach, esophagus, pancreas, urethra, lung, kidney and gallbladder. Mucin is overexpressed in many cancer types, including pancreatic cancer, lung cancer, breast cancer, ovarian cancer, etc. Many studies have been conducted on the pathological relationship between mucin and cancer, in particular, several antibodies against MUC1 known in the art.

[0003] However, their therapeutic effects can still be improved, and therefore, the present application provides anti-MUC1 antibodies or antigen-binding fragments thereof with improved properties.

[0004] public

[0005] Technical issues

[0006] In one aspect, an anti-MUCl antibody or antigen-binding fragment thereof is provided.

[0007] Another aspect provides an anti-MUCl / anti-CD3 bispecific antibody comprising an anti-MUCl antibody or an antigen-binding fragment thereof, and an anti-CD3 antibody or an antigen-binding fragment thereof.

[0008] Other aspects provide a pharmaceutical composition for preventing or treating cancer, comprising (i) an anti-MUC1 antibody or an antigen-binding fragment thereof, or (ii) an anti-MUC1 / anti-CD3 bispecific antibody as an active ingredient.

[0009] Other aspects provide methods for preventing or treating cancer, comprising administering to a subject in need of preventing or treating cancer (i) an anti-MUC1 antibody or an antigen-binding fragment thereof, or (ii) an anti-MUC1 / anti-CD3 bispecific antibody.

[0010] Other aspects provide use of (i) an anti-MUC1 antibody or an antigen-binding fragment thereof, or (ii) an anti-MUC1 / anti-CD3 bispecific antibody for preventing or treating cancer, or use thereof for preparing an anticancer agent.

[0011] Other aspects provide polynucleotides encoding (i) an anti-MUC1 antibody or an antigen-binding fragment thereof, or (ii) an anti-MUC1 / anti-CD3 bispecific antibody, recombinant vectors comprising the polynucleotides, and / or recombinant cells comprising the recombinant vectors.

[0012] Other aspects provide methods for preparing (i) an anti-MUC1 antibody or an antigen-binding fragment thereof, or (ii) an anti-MUC1 / anti-CD3 bispecific antibody, comprising administering a polynucleotide encoding (i) an anti-MUC1 antibody or an antigen-binding fragment thereof, or (ii) an anti-MUC1 / anti-CD3 bispecific antibody.

[0013] Technical Solutions

[0014] Definition of terms

[0015] When the animal-derived antibodies produced by immunizing immunized animals with the desired antigen for therapeutic purposes are applied to people, immune rejection is usually caused. In order to suppress this immune rejection, chimeric antibodies have been developed. Chimeric antibodies are antibodies in which the constant region of an animal-derived antibody that causes an anti-isotype response is replaced by the constant region of a human antibody. Compared with animal-derived antibodies, chimeric antibodies significantly improve anti-isotype responses, but animal-derived amino acids are still present in the variable region, and therefore, there are potential side effects of anti-idiotype responses. Humanized antibodies have been developed to improve these side effects. This is made by transplanting CDR (complementarity determining region) regions, which play an important role in the antigen binding in the variable region of chimeric antibodies to the human antibody framework.

[0016] In a specific embodiment, the anti-MUC1 antibody can be an animal-derived antibody (e.g., a murine antibody), a chimeric antibody (e.g., a human-mouse chimeric antibody), or a humanized antibody. The antibody or antigen-binding fragment can be isolated from a living organism or is non-naturally occurring. The antibody or antigen-binding fragment can be recombinantly produced or synthetically produced. The antibody or antigen-binding fragment can be isolated from a living organism or is non-naturally occurring. The antibody or antigen-binding fragment can be synthetically produced or recombinantly produced.

[0017] In another embodiment, the antibody can be derived from (isolated from) any animal, including mammals such as humans and birds. For example, the antibody can be an antibody of a human, mouse, donkey, sheep, rabbit, goat, guinea pig, camel, horse or chicken. In this article, a human antibody is an antibody having a human immunoglobulin amino acid sequence, including antibodies isolated from a human immunoglobulin library, or antibodies isolated from an animal that has been transfected with at least one human immunoglobulin and does not express endogenous immunoglobulins.

[0018] The anti-MUC1 antibody can be a monoclonal antibody or a polyclonal antibody, for example, a monoclonal antibody. The monoclonal antibody can be prepared according to methods well known in the art. For example, it can be prepared using phage display. Alternatively, the anti-MUC1 antibody can be prepared as a murine monoclonal antibody.

[0019] In the anti-MUC1 antibody or its antigen-binding fragment, other sites besides the heavy chain CDR and light chain CDR regions, or the heavy chain variable region and light chain variable region can be derived from all subtypes of immunoglobulins (e.g., IgA, IgD, IgE, IgG (IgG1, IgG2, IgG3, IgG4), IgM, etc.), for example, they can be derived from framework sites and / or light chain variable regions and / or heavy chain variable regions of all subtypes of immunoglobulins.

[0020] A complete antibody (e.g., IgG type) has a structure of 2 full-length light chains and 2 full-length heavy chains, and each light chain is linked to a heavy chain by a disulfide bond. The variable region of an antibody is divided into a heavy chain variable region and a light chain variable region, and the heavy chain variable region has gamma (γ), mu (μ), alpha (α), delta (δ), and epsilon (ε) types, and has gamma1 (γ1), gamma2 (γ2), gamma3 (γ3), gamma4 (γ4), alpha1 (α1), and alpha2 (α2) as subtypes. The light chain variable region has kappa (κ) and lambda (λ) types.

[0021] The term "heavy chain" is to be interpreted as including the meaning of all full-length heavy chains, which include the variable region domain V H and 3 constant region domains C H1 , C H2 and C H3 and hinge and fragments thereof, the variable region domain V H The term "light chain" is interpreted as including the meaning of a full-length light chain, which includes a variable region domain V L and constant region domain C L and fragments thereof, the variable region domain V L The amino acid sequence comprising variable region sequences sufficient to confer antigen specificity.

[0022] The term "CDR (complementarity determining region)" refers to the amino acid sequence of the hypervariable region of the heavy and light chains of immunoglobulins. The heavy and light chains may contain three CDRs (CDRH1, CDRH2, CDRH3 and CDRL1, CDRL2, CDRL3), respectively. CDRs may provide the main contact residues for the binding of antibodies to antigens or epitopes. On the other hand, in this specification, the terms "specific binding" or "specific recognition" have the same meaning as is well known in the art, and refer to the specific interaction of antigens and antibodies for immune response.

[0023] The term "hinge region" refers to a region contained in an antibody heavy chain, present between the CH1 and CH2 regions, and refers to a region in an antibody that provides flexibility to an antigen binding site.

[0024] When the animal-derived antibody undergoes a chimerization process, the animal-derived IgG1 hinge is replaced by a human IgG1 hinge, but the animal-derived IgG1 hinge has a shorter length than the human IgG1 hinge, and the disulfide bonds between its two heavy chains are reduced from 3 to 2, thus showing different hinge rigidity effects from each other. Therefore, modification of the hinge region can increase the antigen binding efficiency of the humanized antibody. Methods for deleting, adding or substituting amino acids to modify the hinge region amino acid sequence are well known in the art.

[0025] "Antigen binding fragment" is a fragment of the complete structure of an immunoglobulin, and refers to a part of a polypeptide that contains an antigen-binding portion. For example, it can be scFv, (scFv)2, scFvFc, Fab, Fab' or F(ab')2, but is not limited thereto. In the present invention, the antigen binding fragment of an antibody can be an antigen fragment containing at least one complementary determining region, for example, it can be selected from scFv, (scFv)2, scFv-Fc, Fab, Fab' and F(ab')2. Antigen binding fragments can be obtained using proteases (for example, Fab can be obtained by restrictive cleavage of the whole antibody with papain, and F(ab')2 fragments can be obtained by cleavage with pepsin), and can be manufactured by genetic recombination technology.

[0026] The Fab antigen-binding fragment has a light chain and a heavy chain variable region, a light chain constant region and a heavy chain first constant region (C H1 ) structure and has an antigen binding site.

[0027] Fab' differs from Fab in that it has a hinge region containing at least one cysteine ​​residue located between the C H1 C-terminal of the domain. F(ab')2 antibodies are generated by the formation of disulfide bonds between cysteine ​​residues in the hinge region.

[0028] Fv is the smallest antibody fragment with only heavy chain variable region and light chain variable region, and the recombinant technology of producing Fv fragment is well known in the art. In double-chain Fv, heavy chain variable region and light chain variable region are connected by non-covalent bonds, while in single-chain Fv (scFv), usually through peptide linker, heavy chain variable region and single chain variable region are connected by covalent bonds or directly connected at C-terminus, therefore, it can form the same dimer structure as double-chain Fv. Peptide linker can be the same as described above, for example, its length can be 1 to 100 amino acids, for example, 2 to 50 amino acids in length, or 5 to 25 amino acids in length, and there is no restriction on the type of amino acids contained therein.

[0029] Antigen-binding fragments can be obtained using proteases (for example, Fab can be obtained by restrictive cleavage of whole antibodies with papain, and F(ab')2 fragments can be obtained by cleavage with pepsin), and can be produced by genetic recombination techniques.

[0030] In an antigen binding fragment such as scFV, the heavy chain variable region and the light chain variable region may be connected by or without a joint such as a peptide joint. The peptide joint may be a polypeptide consisting of 1 to 100 or 2 to 50 amino acids, and there is no restriction on the type of amino acids contained therein. The peptide joint may include, for example, Gly, Asn and / or Ser residues, and may also include neutral amino acids such as Thr and / or Ala. As long as the function of the bispecific antibody is not affected, the length of the joint may be determined differently. For example, the peptide joint may include a total of 1 to 100, 2 to 50 or 5 to 25 at least one amino acid selected from Gly, Asn, Ser, Thr and Ala. In one embodiment, the peptide joint may be expressed as (G4S)n (n is the number of repetitions of (G4S), an integer of 1 to 10, such as an integer of 2 to 5).

[0031] The term "antagonist" is interpreted as a concept that includes all molecules that partially or completely block, inhibit or neutralize at least one biological activity of a target (e.g., MUC1). For example, an "antagonist" antibody refers to an antibody that inhibits or reduces the biological activity of an antigen to which the antibody binds (e.g., MUC1). The antagonist can reduce receptor phosphorylation by binding to the receptor of the ligand (target), or incapacitate or kill cells activated by the ligand. In addition, the antagonist can completely disrupt the receptor-ligand interaction, compete with the ligand for receptor binding, or significantly reduce the receptor-ligand interaction by changing or downregulating the tertiary structure of the receptor.

[0032] Anti-MUC1 antibody or antigen-binding fragment thereof

[0033] One embodiment of the present invention provides a polypeptide capable of specifically recognizing and / or specifically binding to MUC1 (mucin-1).

[0034] MUC1 can be human MUC1, or MUC1 of monkey, dog, rat or mouse, etc. In one embodiment, human MUC1 can be MUC1 isoform M2 (identifier: A6ZID5; NCBI reference number: ABS01294.1), MUC1 isoform 1 (identifier: P15941-1), MUC1 isoform 2 (identifier: P15941-2), MUC1 isoform 3 (identifier: P15941-3), MUC1 isoform 4 (identifier: P15941-4), MUC1 isoform 5 (identifier: P15941-5), MUC1 isoform 6 (identifier: P15941-6), MUC1 isoform Y (identifier: P15941-7), MUC1 isoform 8 (identifier: P15941-9). -8), MUC1 isoform 9 (identifier: P15941-9), MUC1 isoform F (identifier: P15941-10), MUC1 isoform Y-LSP (identifier: P15941-11), MUC1 isoform S2 (identifier: P15941-12), MUC1 isoform M6 (identifier: P15941-13), MUC1 isoform ZD (identifier: P15941-14), MUC1 isoform T10 (identifier: P15941-15), MUC1 isoform E2 (identifier: P15941-16) or MUC1 isoform J13 (identifier: P15941-17), etc., but are not limited to these.

[0035] In one embodiment, human MUCl can have an amino acid sequence as provided in the following NCBI reference sequence: NP_001018016.1, NP_001018017.1, NP_001037855.1, NP_001037856.1, NP_001037857.1, NP_001037858.1, NP_001191214.1, NP_001191215.1, NP_001191216.1 , NP_001191217.1, NP_001191218.1, NP_001191219.1, NP_001191220.1, NP_001191221.1, NP_001191222.1, NP_001191223.1, NP_001191224.1, NP_001191225.1, NP_001191226.1, NP_002447.4, etc., but not limited to these, and And each amino acid sequence can be encoded by the nucleotide sequence (mRNA) provided in the following NCBI reference sequence: NM_001018016.2, NM_001018017.2, NM_001044390.2, NM_001044391.2, NM_001044392.2, NM_001044393.2, NM_001204285.1, NM_001204286.1, NM_001204287 .1, NM_001204288.1, NM_001204289.1, NM_001204290.1, NM_001204291.1, NM_001204292.1, NM_001204293.1, NM_001204294.1, NM_001204295.1, NM_001204296.1, NM_001204297.1, NM_002456.5, etc., but are not limited to these.

[0036] In the present specification, a protein, polypeptide or polynucleotide having an amino acid sequence or a nucleotide sequence may be used to indicate all cases where the protein, polypeptide or polynucleotide comprises the sequence, consists essentially of the sequence, or consists of the sequence.

[0037] These polypeptides can be used as complementarity determining regions (CDRs) of anti-MUCl antibodies. The complementarity determining regions can then be determined by all common methods, for example, they can be determined by the IMGT definition (http: / / www.imgt.org / IMGT_vquest / share / textes / ) or the Kabat definition (http: / / www.bioinf.org.uk / abs / ), but are not limited thereto.

[0038] In other embodiments, a MUCl targeting polypeptide molecule is provided, which comprises at least one polypeptide selected from the following group.

[0039] The MUC1 targeting polypeptide molecule may comprise the heavy chain complementary determining region and the light chain complementary determining region of the aforementioned anti-MUC1 antibody, or a combination thereof; or a heavy chain variable region comprising the heavy chain complementary determining region, a light chain variable region comprising the light chain complementary determining region, or a combination thereof.

[0040] The MUC1 targeting polypeptide molecule is not limited thereto, but can be used as an anti-MUC1 antibody, an antigen-binding fragment of an antibody, or an analog of an anti-MUC1 antibody (a structure having a similar backbone and function to an antibody; such as a peptibody, a nanobody, etc.), or a precursor or component (such as a CDR), such as a multi-binding antibody, etc.

[0041] The term "peptide body (peptide + antibody)" is a fusion protein of a peptide and all or part of the constant region of an antibody, such as an Fc region, and refers to a protein having a skeleton and function similar to an antibody. In this article, at least one of the above peptides can serve as an antigen binding site (heavy chain and / or light chain CDR or variable region).

[0042] The term "nanobody", also known as single-domain antibody, refers to an antibody fragment comprising a single variable domain of an antibody in monomeric form, and has the property of selectively binding to a specific antigen similar to that of an antibody in a complete structure. The molecular weight of a nanobody is typically about 12 kDa to about 15 kDa, which is very small compared to the general molecular weight (about 150 kDa to about 160 kDa) of a complete antibody (comprising two heavy chains and two light chains), and in some cases, it is smaller than a Fab fragment or a scFv fragment.

[0043] Specifically, the present invention provides a polypeptide capable of specifically recognizing and / or specifically binding to MUC1. The polypeptide may comprise at least one amino acid sequence selected from SEQ ID NO: 1, SEQ ID NO: 7, SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 27 and SEQ ID NO: 33, and more specifically, it may have at least one amino acid sequence selected from SEQ ID NO: 2 to SEQ ID NO: 6, SEQ ID NO: 8 to SEQ ID NO: 15, SEQ ID NO: 17 to SEQ ID NO: 18, SEQ ID NO: 20 to SEQ ID NO: 26, SEQ ID NO: 28 to SEQ ID NO: 32, and SEQ ID NO: 34 and SEQ ID NO: 38.

[0044] The polypeptides and their applicable complementary determining regions are summarized in Table 1 below. In Table 1 below, V H -CDR1, VH -CDR2 and V H -CDR3 refers to the heavy chain complementarity determining region, V L -CDR1, V L -CDR2 and V L - CDR3 refers to the light chain complementarity determining region.

[0045] [Table 1]

[0046]

[0047]

[0048]

[0049] In one embodiment, an anti-MUCl antibody or antigen-binding fragment thereof is provided, which comprises at least one polypeptide selected as a complementarity determining region.

[0050] The anti-MUC1 antibody or antigen-binding fragment thereof may comprise at least one selected from the group consisting of

[0051] a polypeptide having the amino acid sequence of SEQ ID NO: 1 (VH-CDR1),

[0052] A polypeptide having the amino acid sequence of SEQ ID NO: 7 (VH-CDR2), and

[0053] a polypeptide having the amino acid sequence of SEQ ID NO: 16 (VH-CDR3),

[0054] Serves as the heavy chain complementarity determining region.

[0055] The amino acid sequence of SEQ ID NO: 1 is identical to the amino acid sequence of the following general formula 1:

[0056] [General formula 1] (SEQ ID NO: 1)

[0057]

[0058] X1 is D or S,

[0059] X2 is N, S or H.

[0060] In one embodiment, the polypeptide of SEQ ID NO: 1 that can be used as the light chain CDR1 of an anti-MUC1 antibody or an antigen-binding fragment thereof may have at least one amino acid sequence selected from, for example, SEQ ID NO: 2 to SEQ ID NO: 6, the detailed sequences of which are described in Table 1 above and the sequence listing, and the bold underlined portions in the amino acid sequence represent modified amino acids.

[0061] The amino acid sequence of SEQ ID NO: 7 is identical to the amino acid sequence of the following general formula 2:

[0062] [Formula 2] (SEQ ID NO: 7)

[0063]

[0064] X is Q, F or V,

[0065] X4 is R or K,

[0066] X5 is N, S, Q or Y,

[0067] X6 is P or A,

[0068] X7 is N or G,

[0069] X8 is Y, G or S,

[0070] X9 is E or T,

[0071] X10 is T or K,

[0072] X11 is Y or E,

[0073] X12 is S, A or V,

[0074] X13 is N, Q or A.

[0075] In one embodiment, the polypeptide of SEQ ID NO: 7 that can be used as the heavy chain CDR2 of an anti-MUC1 antibody or an antigen-binding fragment thereof may have at least one amino acid sequence selected from, for example, SEQ ID NO: 8 to SEQ ID NO: 15, the detailed sequences of which are described in Table 1 above and the sequence listing, and the bold underlined portions in the amino acid sequences represent modified amino acids.

[0076] The amino acid sequence of SEQ ID NO: 16 is identical to the amino acid sequence of the following general formula 3:

[0077] [General Formula 3] (SEQ ID NO: 16)

[0078]

[0079] X14 is M or F.

[0080] In one embodiment, the polypeptide of SEQ ID NO: 16 that can be used as the heavy chain CDR3 of an anti-MUC1 antibody or an antigen-binding fragment thereof may have at least one amino acid sequence selected from, for example, SEQ ID NO: 17 to SEQ ID NO: 18, the detailed sequences of which are described in Table 1 above and the sequence listing, and the bold underlined portions in the amino acid sequences represent modified amino acids.

[0081] The anti-MUC1 antibody or antigen-binding fragment thereof may comprise at least one selected from the group consisting of

[0082] a polypeptide having the amino acid sequence of SEQ ID NO: 19 (VL-CDR1),

[0083] a polypeptide having the amino acid sequence of SEQ ID NO: 27 (VL-CDR2), and

[0084] a polypeptide having the amino acid sequence of SEQ ID NO: 33 (VL-CDR3),

[0085] Serves as the light chain complementarity determining region.

[0086] The amino acid sequence of SEQ ID NO: 19 is identical to the amino acid sequence of the following general formula 4:

[0087] [Formula 4] (SEQ ID NO: 19)

[0088]

[0089] X15 is K or R,

[0090] X16 is S or A,

[0091] X17 is L or V,

[0092] X18 is L, Y or H,

[0093] X19 is N or S,

[0094] X20 is Q or G,

[0095] X21 is K or Y.

[0096] In one embodiment, the polypeptide of SEQ ID NO: 19 that can be used as the light chain CDR1 of an anti-MUC1 antibody or an antigen-binding fragment thereof may have at least one amino acid sequence selected from, for example, SEQ ID NO: 20 to SEQ ID NO: 26, the detailed sequences of which are described in Table 1 above and the sequence listing, and the bold underlined portions in the amino acid sequences represent modified amino acids.

[0097] The amino acid sequence of SEQ ID NO: 27 is identical to the amino acid sequence of the following general formula 5:

[0098] [Formula 5] (SEQ ID NO: 27)

[0099]

[0100] X22 is A or G,

[0101] X23 is T or S,

[0102] X24 is E or A,

[0103] X25 is S or T.

[0104] In one embodiment, the polypeptide of SEQ ID NO: 27 that can be used as the light chain CDR2 of an anti-MUC1 antibody or an antigen-binding fragment thereof may have at least one amino acid sequence selected from, for example, SEQ ID NO: 28 to SEQ ID NO: 32, the detailed sequences of which are described in Table 1 above and the sequence listing, and the bold underlined portions in the amino acid sequences represent modified amino acids.

[0105] The amino acid sequence of SEQ ID NO: 33 is identical to the amino acid sequence of the following general formula 6:

[0106] [General Formula 6] (SEQ ID NO: 33)

[0107]

[0108] X26 is C or S,

[0109] X27 is S or Q,

[0110] X28 is Y, T or S,

[0111] X29 is L or Y.

[0112] In one embodiment, the polypeptide of SEQ ID NO: 27 that can be used as the light chain CDR3 of an anti-MUC1 antibody or an antigen-binding fragment thereof may have at least one amino acid sequence selected from, for example, SEQ ID NO: 34 to SEQ ID NO: 38, the detailed sequences of which are described in Table 1 above and the sequence listing, and the bold underlined portions in the amino acid sequences represent modified amino acids.

[0113] In one embodiment, the anti-MUC1 antibody or antigen-binding fragment thereof may comprise

[0114] at least one heavy chain complementarity determining region selected from a polypeptide having the amino acid sequence of SEQ ID NO: 1 (VH-CDR1), a polypeptide having the amino acid sequence of SEQ ID NO: 7 (VH-CDR2), and a polypeptide having the amino acid sequence of SEQ ID NO: 16 (VH-CDR3), or a heavy chain variable region comprising at least one heavy chain complementarity determining region;

[0115] at least one light chain complementarity determining region selected from a polypeptide having the amino acid sequence of SEQ ID NO: 19 (VL-CDR1), a polypeptide having the amino acid sequence of SEQ ID NO: 27 (VL-CDR2), and a polypeptide having the amino acid sequence of SEQ ID NO: 33 (VL-CDR3), or a light chain variable region comprising at least one light chain complementarity determining region;

[0116] A combination of a heavy chain complementarity determining region and a light chain complementarity determining region; or

[0117] Combination of a heavy chain variable region and a light chain variable region.

[0118] In one embodiment, the anti-MUC1 antibody or antigen-binding fragment thereof may comprise

[0119] at least one heavy chain complementarity determining region selected from a polypeptide having an amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 6 (VH-CDR1), a polypeptide having an amino acid sequence of SEQ ID NO: 8 to SEQ ID NO: 16 (VH-CDR2), and a polypeptide having an amino acid sequence of SEQ ID NO: 17 to SEQ ID NO: 18 (VH-CDR3), or a heavy chain variable region comprising at least one heavy chain complementarity determining region;

[0120] at least one light chain complementarity determining region selected from a polypeptide having an amino acid sequence of SEQ ID NO: 20 to SEQ ID NO: 26 (VL-CDR1), a polypeptide having an amino acid sequence of SEQ ID NO: 28 to SEQ ID NO: 32 (VL-CDR2), and a polypeptide having an amino acid sequence of SEQ ID NO: 34 to SEQ ID NO: 38 (VL-CDR3), or a light chain variable region comprising at least one light chain complementarity determining region;

[0121] A combination of a heavy chain complementarity determining region and a light chain complementarity determining region; or

[0122] Combination of a heavy chain variable region and a light chain variable region.

[0123] In one embodiment, the anti-MUC1 antibody or antigen-binding fragment thereof may comprise

[0124] a heavy chain variable region comprising a polypeptide having an amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 6 (VH-CDR1), a polypeptide having an amino acid sequence of SEQ ID NO: 8 to SEQ ID NO: 16 (VH-CDR2), and a polypeptide having an amino acid sequence of SEQ ID NO: 17 to SEQ ID NO: 18 (VH-CDR3); and

[0125] A light chain variable region comprising a polypeptide having an amino acid sequence of SEQ ID NO: 20 to SEQ ID NO: 26 (VL-CDR1), a polypeptide having an amino acid sequence of SEQ ID NO: 28 to SEQ ID NO: 32 (VL-CDR2), and a polypeptide having an amino acid sequence of SEQ ID NO: 34 to SEQ ID NO: 38 (VL-CDR3).

[0126] In one embodiment, an anti-MUCl antibody or antigen-binding fragment thereof may comprise the heavy chain variable region CDR sequences and light chain variable region CDR sequences in combination in Tables 2 and 3 below.

[0127] [Table 2]

[0128]

[0129] [Table 3]

[0130]

[0131] In one embodiment, the anti-MUC1 antibody or antigen-binding fragment thereof may comprise

[0132] at least one heavy chain complementarity determining region selected from a polypeptide having an amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4 (VH-CDR1), a polypeptide having an amino acid sequence of SEQ ID NO: 8, SEQ ID NO: 9 or SEQ ID NO: 14 (VH-CDR2), and a polypeptide having an amino acid sequence of SEQ ID NO: 17 (VH-CDR3), or a heavy chain variable region comprising at least one heavy chain complementarity determining region;

[0133] at least one light chain complementarity determining region selected from a polypeptide having an amino acid sequence of SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, or SEQ ID NO: 24 (VL-CDR1), a polypeptide having an amino acid sequence of SEQ ID NO: 28, SEQ ID NO: 29, or SEQ ID NO: 31 (VL-CDR2), and a polypeptide having an amino acid sequence of SEQ ID NO: 34, SEQ ID NO: 35, or SEQ ID NO: 36 (VL-CDR3), or a light chain variable region comprising at least one light chain complementarity determining region;

[0134] A combination of a heavy chain complementarity determining region and a light chain complementarity determining region; or

[0135] Combination of a heavy chain variable region and a light chain variable region.

[0136] In one embodiment, the anti-MUC1 antibody or antigen-binding fragment thereof may comprise

[0137] at least one heavy chain complementarity determining region selected from a polypeptide having the amino acid sequence of SEQ ID NO: 2 (VH-CDR1), a polypeptide having the amino acid sequence of SEQ ID NO: 8 or SEQ ID NO: 9 (VH-CDR2), and a polypeptide having the amino acid sequence of SEQ ID NO: 17 (VH-CDR3), or a heavy chain variable region comprising at least one heavy chain complementarity determining region;

[0138] at least one light chain complementarity determining region selected from a polypeptide having an amino acid sequence of SEQ ID NO: 21, SEQ ID NO: 23, or SEQ ID NO: 24 (VL-CDR1), a polypeptide having an amino acid sequence of SEQ ID NO: 28 or SEQ ID NO: 29 (VL-CDR2), and a polypeptide having an amino acid sequence of SEQ ID NO: 34 or SEQ ID NO: 35 (VL-CDR3), or a light chain variable region comprising at least one light chain complementarity determining region;

[0139] A combination of a heavy chain complementarity determining region and a light chain complementarity determining region; or

[0140] Combination of a heavy chain variable region and a light chain variable region.

[0141] In one embodiment, the anti-MUC1 antibody or antigen-binding fragment thereof may comprise

[0142] 1) a polypeptide having an amino acid sequence of SEQ ID NO: 2 (VH-CDR1), a polypeptide having an amino acid sequence of SEQ ID NO: 9 (VH-CDR2), a polypeptide having an amino acid sequence of SEQ ID NO: 17 (VH-CDR3), a polypeptide having an amino acid sequence of SEQ ID NO: 21 (VL-CDR1), a polypeptide having an amino acid sequence of SEQ ID NO: 28 (VL-CDR2), and a polypeptide having an amino acid sequence of SEQ ID NO: 35 (VL-CDR3);

[0143] 2) a polypeptide having an amino acid sequence of SEQ ID NO: 2 (VH-CDR1), a polypeptide having an amino acid sequence of SEQ ID NO: 9 (VH-CDR2), a polypeptide having an amino acid sequence of SEQ ID NO: 17 (VH-CDR3), a polypeptide having an amino acid sequence of SEQ ID NO: 23 (VL-CDR1), a polypeptide having an amino acid sequence of SEQ ID NO: 28 (VL-CDR2), and a polypeptide having an amino acid sequence of SEQ ID NO: 36 (VL-CDR3);

[0144] 3) a polypeptide having an amino acid sequence of SEQ ID NO: 2 (VH-CDR1), a polypeptide having an amino acid sequence of SEQ ID NO: 9 (VH-CDR2), a polypeptide having an amino acid sequence of SEQ ID NO: 17 (VH-CDR3), a polypeptide having an amino acid sequence of SEQ ID NO: 24 (VL-CDR1), a polypeptide having an amino acid sequence of SEQ ID NO: 29 (VL-CDR2), and a polypeptide having an amino acid sequence of SEQ ID NO: 35 (VL-CDR3);

[0145] 4) a polypeptide having the amino acid sequence of SEQ ID NO: 2 (VH-CDR1), a polypeptide having the amino acid sequence of SEQ ID NO: 8 (VH-CDR2), a polypeptide having the amino acid sequence of SEQ ID NO: 17 (VH-CDR3), a polypeptide having the amino acid sequence of SEQ ID NO: 23 (VL-CDR1), a polypeptide having the amino acid sequence of SEQ ID NO: 28 (VL-CDR2), and a polypeptide having the amino acid sequence of SEQ ID NO: 34 (VL-CDR3); or

[0146] 5) a polypeptide having an amino acid sequence of SEQ ID NO: 2 (VH-CDR1), a polypeptide having an amino acid sequence of SEQ ID NO: 8 (VH-CDR2), a polypeptide having an amino acid sequence of SEQ ID NO: 17 (VH-CDR3), a polypeptide having an amino acid sequence of SEQ ID NO: 24 (VL-CDR1), a polypeptide having an amino acid sequence of SEQ ID NO: 29 (VL-CDR2), and a polypeptide having an amino acid sequence of SEQ ID NO: 35 (VL-CDR3).

[0147] The anti-MUC1 antibody or antigen-binding fragment thereof may comprise at least one framework sequence of a heavy chain variable region, at least one framework sequence of a light chain variable region, or at least one framework sequence of a heavy chain variable region and at least one framework sequence of a light chain variable region. An example of a framework sequence of a heavy chain variable region and a framework sequence of a light chain variable region is shown in Tables 4 to 7 below.

[0148] [Table 4]

[0149]

[0150] [Table 5]

[0151]

[0152] [Table 6]

[0153]

[0154] [Table 7]

[0155]

[0156] In one embodiment, the anti-MUC1 antibody or antigen-binding fragment thereof can be a heavy chain variable region comprising a heavy chain complementary determining region (VH0 to VH9 in Table 2 above), a light chain variable region comprising a light chain complementary determining region (VL0 to VL9 in Table 3 above), or a combination thereof. For example, the heavy chain variable region can comprise an amino acid sequence selected from SEQ ID NO: 77 to SEQ ID NO: 86, and the light chain variable region can comprise an amino acid sequence selected from SEQ ID NO: 87 to SEQ ID NO: 96. For example, the heavy chain variable region can comprise an amino acid sequence selected from SEQ ID NO: 77 to SEQ ID NO: 86, and the light chain variable region can comprise an amino acid sequence selected from SEQ ID NO: 87 to SEQ ID NO: 96.

[0157] Thus, the anti-MUC1 antibody or antigen-binding fragment thereof may comprise

[0158] a heavy chain variable region having an amino acid sequence selected from the group consisting of SEQ ID NO: 77 to SEQ ID NO: 86;

[0159] A light chain variable region having an amino acid sequence selected from the group consisting of SEQ ID NO: 87 to SEQ ID NO: 96; or

[0160] Its combination.

[0161] In one embodiment, the anti-MUC1 antibody or antigen-binding fragment thereof may comprise

[0162] a heavy chain variable region having the amino acid sequence of SEQ ID NO: 78, SEQ ID NO: 81, SEQ ID NO: 84 or SEQ ID NO: 85; and

[0163] A light chain variable region having the amino acid sequence of SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:94 or SEQ ID NO:95.

[0164] In one embodiment, the anti-MUC1 antibody or antigen-binding fragment thereof may comprise

[0165] a heavy chain variable region having the amino acid sequence of SEQ ID NO: 78, SEQ ID NO: 81 or SEQ ID NO: 84; and

[0166] A light chain variable region having the amino acid sequence of SEQ ID NO:89, SEQ ID NO:91 or SEQ ID NO:92.

[0167] In one embodiment, the anti-MUC1 antibody or antigen-binding fragment thereof may comprise

[0168] 1) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 78 and a light chain variable region having the amino acid sequence of SEQ ID NO: 89;

[0169] 2) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 78 and a light chain variable region having the amino acid sequence of SEQ ID NO: 91;

[0170] 3) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 78 and a light chain variable region having the amino acid sequence of SEQ ID NO: 92;

[0171] 4) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 81 and a light chain variable region having the amino acid sequence of SEQ ID NO: 91;

[0172] 5) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 81 and a light chain variable region having the amino acid sequence of SEQ ID NO: 92; or

[0173] 6) a heavy chain variable region having the amino acid sequence of SEQ ID NO: 84 and a light chain variable region having the amino acid sequence of SEQ ID NO: 91.

[0174] The term "epitope" is to be interpreted as an antigenic determinant, ie, a portion of an antigen that is recognized by an antibody. In a specific embodiment, the epitope may be a polypeptide comprising a region within the MUCl protein, such as the amino acid sequence of SEQ ID NO:109.

[0175] Thus, the anti-MUCl antibody or antigen-binding fragment can specifically bind to an epitope comprising the amino acid sequence of SEQ ID NO:109.

[0176] Multiplex conjugated antibodies

[0177] One embodiment of the present invention relates to a multi-binding antibody or a multispecific antibody comprising a polypeptide that can specifically recognize and / or specifically bind to MUC1, more specifically, it can be a bispecific antibody comprising a polypeptide that can specifically recognize and / or specifically bind to a second target and a polypeptide that can specifically recognize and / or specifically bind to MUC1.

[0178] In the present specification, the term "multi-binding antibody" refers to an antibody that recognizes and / or binds to two or more different antigens, or recognizes and / or binds to different sites of the same antigen, and one antigen binding site of the multi-binding antibody may contain the above-mentioned polypeptide.

[0179] Another embodiment of the present invention relates to a bispecific antigen binding molecule comprising a first antigen binding domain that specifically binds to MUC1 and a second antigen binding domain that specifically binds to CD3. Specifically, one embodiment of the present invention relates to a bispecific antibody comprising at least one antigen binding site specific for a MUC1 antibody or antigen binding fragment thereof according to the present invention and a T cell activation antigen.

[0180] In the bispecific antibody, the T cell activating antigen can be a CD3 T cell co-receptor (CD3; cluster of differentiation 3) antigen (e.g., an anti-CD3 epsilon (ε) antigen), and the bispecific antibody can include an anti-CD3 antibody comprising an antigen binding site for the CD3 antigen or an antigen-binding fragment thereof.

[0181] Specifically, it relates to a bispecific antibody comprising an anti-MUC1 antibody or an antigen-binding fragment thereof and an anti-CD3 antibody or an antigen-binding fragment thereof (in other words, an anti-MUC1 / anti-CD3 bispecific antibody). The anti-MUC1 / anti-CD3 bispecific antibody can exhibit a synergistic effect while maintaining affinity and activity for each of the MUC1 and CD3 antigens.

[0182] The bispecific antibody specifically binds to the first antigen MUCl and may comprise an anti-MUCl antibody or an antigen-binding fragment thereof. The anti-MUCl antibody or antigen-binding fragment thereof may be the same as described above.

[0183] In addition, the bispecific antibody specifically binds to a second antigen CD3, and specifically, it may comprise an anti-CD3 antibody or an antigen binding fragment thereof. The anti-CD3 antibody or antigen binding fragment may be an antibody or an antigen binding fragment thereof that binds to CD3 of humans, monkeys, mice, etc. The anti-CD3 antibody or its antigen binding fragment may be used to target T cells expressing CD3, or to stimulate T cell activation. The anti-CD3 antibody or its antigen binding fragment of the present invention may be used as part of a bispecific antibody that directs CD3-mediated T cell activation against specific cell types, such as tumor cells or infectious pathogens.

[0184] Anti-CD3 antibodies or antigen-binding fragments thereof can be used without limitation as long as they are antibodies that specifically bind to CD3, such as OKT3 antibodies or antigen-binding fragments thereof, UCHT-1 antibodies or antigen-binding fragments thereof, SP34 antibodies or antigen-binding fragments thereof, etc., but are not limited thereto. The OKT3 antibody may be a mouse or humanized immunoglobulin IgG2a isotype monoclonal antibody. The UCHT-1 antibody is known to react with the approximately 20 kDa CD3ε small unit of the human T cell receptor (TCR) / CD3 complex, and the SP34 antibody is known to bind to the CD3ε small unit. Methods for obtaining the OKT3 antibody, UCHT-1 antibody, or SP34 antibody are well known in the art.

[0185] In a specific embodiment, the anti-CD3 antibody or antigen-binding fragment thereof may comprise at least one CDR sequence, preferably 6 CDR sequences, selected from the following polypeptides (see Table 8 below):

[0186] a polypeptide having the amino acid sequence of SEQ ID NO: 97 (VH-CDR1),

[0187] a polypeptide having the amino acid sequence of SEQ ID NO: 98 (VH-CDR2),

[0188] a polypeptide having the amino acid sequence of SEQ ID NO: 99 (VH-CDR3),

[0189] a polypeptide having the amino acid sequence of SEQ ID NO: 100 (VL-CDR1),

[0190] A polypeptide having the amino acid sequence of SEQ ID NO: 101 (VL-CDR2), and

[0191] A polypeptide having the amino acid sequence of SEQ ID NO: 102 (VL-CDR3).

[0192] More specifically, an anti-CD3 antibody or antigen-binding fragment thereof

[0193] It may comprise a heavy chain variable region having the amino acid sequence of SEQ ID NO: 103, and a light chain variable region having the amino acid sequence of SEQ ID NO: 104 or SEQ ID NO: 105.

[0194] [Table 8]

[0195]

[0196] The antigen-binding fragment of the anti-CD3 antibody may be selected from scFv, (scFv)2, Fab, Fab' and F(ab')2 of the anti-CD3 antibody.

[0197] The anti-MUC1 / anti-CD3 bispecific antibody according to the present invention may be an antibody in which an anti-CD3 antibody or an antigen-binding fragment thereof is linked to the C-terminus or N-terminus of an anti-MUC1 antibody or an antigen-binding fragment thereof.

[0198] For example, it can be an anti-CD3 antibody scFv that binds to the N-terminus or C-terminus of the heavy chain of an anti-MUC1 antibody or an antigen-binding fragment thereof (anti-MUC1 heavy chain N-terminus-anti-CD3 scFv or anti-MUC1 heavy chain C-terminus-anti-CD3 scFv), or an anti-CD3 antibody scFv that binds to the N-terminus or C-terminus of the anti-MUC1 light chain (anti-MUC1 light chain N-terminus-anti-CD3 scFv or anti-MUC1 light chain C-terminus-anti-CD3 scFv). In addition, it can be a bispecific antibody in the form of having one antigen-binding site of an anti-MUC1 antibody and one antigen-binding site of an anti-CD3 antibody (1+1), two of the three antigen-binding sites of a bispecific antibody and one (1+2 or 2+1), or two of the four antigen-binding sites (2+2), including bispecific antibodies in which the anti-CD3 scFv binds in a monovalent or divalent form, but is not limited thereto.

[0199] In one embodiment, the anti-MUC1 / anti-CD3 bispecific antibody may comprise an anti-MUC1 antibody or an antigen-binding fragment thereof, and an anti-CD3 antibody or an antigen-binding fragment thereof connected to the C-terminus or N-terminus of the heavy chain or light chain, for example, the N-terminus of the light chain of the anti-MUC1 antibody or its antigen-binding fragment. In one embodiment, the anti-MUC1 / anti-CD3 bispecific antibody may comprise a complete anti-MUC1 antibody (e.g., an IgG-type antibody) and an antigen-binding fragment of an anti-CD3 antibody (e.g., scFv, (scFv)2, scFv-Fc, Fab, Fab', and F(ab')2), which is connected to the N-terminus of the antibody light chain.

[0200] In the anti-MUC1 / anti-CD3 bispecific antibody, the anti-MUC1 antibody or its antigen-binding fragment and the anti-CD3 antibody or its antigen-binding fragment may be connected by a linker or not, such as a peptide linker. In addition, the heavy chain portion and the light chain portion in the antigen-binding fragment, such as the heavy chain variable region and the light chain variable region in the scFv fragment, may also be connected by a peptide linker or not. The peptide linker connecting the anti-MUC1 antibody or antigen-binding fragment and the anti-CD3 antibody or its antigen-binding fragment, and the peptide linker connecting the heavy chain portion and the light chain portion in the antigen-binding fragment may be the same or different. The peptide linker may be a polypeptide consisting of 1 to 100 or 2 to 50 amino acids, and the type of amino acids contained therein is not limited. The peptide linker may contain, for example, Gly, Asn and / or Ser residues, and may also contain neutral amino acids such as Thr and / or Ala. Amino acid sequences suitable for peptide linkers are known in the art. On the other hand, the length of the linker may be determined differently as long as it does not affect the function of the bispecific antibody. For example, the peptide linker may consist of a total of 1 to 100, 2 to 50, or 5 to 25 at least one amino acid sequence selected from Gly, Asn, Ser, Thr, and Ala. In one embodiment, the peptide linker may be represented as (G4S)n (n is the number of repetitions of (G4S), an integer from 1 to 10, such as an integer from 2 to 5).

[0201] In one embodiment, the anti-MUC1 / anti-CD3 bispecific antibody may be an scFv form of an anti-CD3 antibody that binds to the N-terminus of a light chain located in the anti-MUC1 antibody or an antigen-binding fragment thereof. The anti-MUC1 / anti-CD3 bispecific antibody in which the anti-CD3 antibody scFv binds to the N-terminus of a light chain located in the anti-MUC1 antibody or an antigen-binding fragment thereof may have a more excellent anti-cancer cell cytotoxicity, cancer cell proliferation inhibitory effect, and / or cancer therapeutic effect than the anti-MUC1 / anti-CD3 bispecific antibody in which the anti-CD3 antibody scFv binds to the C-terminus of a light chain located in the anti-MUC1 antibody or an antigen-binding fragment thereof.

[0202] Medical Uses

[0203] Other aspects provide a pharmaceutical composition for preventing or treating cancer, comprising an anti-MUC1 antibody or antigen-binding fragment, or an anti-MUC1 / anti-CD3 bispecific antibody or antigen-binding fragment.

[0204] Other aspects provide methods for preventing or treating cancer, comprising administering a pharmaceutically effective dose of an anti-MUC1 antibody or antigen-binding fragment, or an anti-MUC1 / anti-CD3 bispecific antibody or antigen-binding fragment to a subject in need of prevention or treatment of cancer. The method for preventing and / or treating cancer may also include confirming that the patient needs to prevent and / or treat cancer before administration.

[0205] Anti-MUC1 antibodies or antigen-binding fragments, or anti-MUC1 / anti-CD3 bispecific antibodies or antigen-binding fragments can be effectively used to prevent or treat cancer. The anti-MUC1 antibodies or antigen-binding fragments, or anti-MUC1 / anti-CD3 bispecific antibodies or antigen-binding fragments provided in this specification exhibit functions as MUC1 agonists, and therefore, in order for the anti-MUC1 antibodies or antigen-binding fragments, or anti-MUC1 / anti-CD3 bispecific antibodies or antigen-binding fragments to exhibit efficacy (e.g., anti-cancer efficacy, such as cancer cell death, etc.), for the applied cancer, corresponding cancer cells expressing MUC1 may be advantageous, for example, it can be a solid cancer expressing MUC1. Specifically, one embodiment of the present invention relates to a novel antibody that specifically binds to MUC-1 and its use, wherein the antibody has improved solid cancer target tropism and therapeutic properties. In one embodiment, the cancer may include at least one selected from blood cancer (e.g., B-cell lymphoma, etc.), osteomyelitis, thyroid cancer, uterine cancer (e.g., cervical cancer), skin cancer, melanoma, breast cancer, colorectal cancer, lung cancer, gastric cancer, prostate cancer and pancreatic cancer, or a solid cancer in which the epitope of the antigen to which the anti-MUC1 antibody or antigen-binding fragment specifically binds is expressed to 30% or higher, but is not limited thereto.

[0206] In the pharmaceutical composition or method, a pharmaceutically effective dose of an anti-MUC1 antibody or antigen-binding fragment thereof or an anti-MUC1 / anti-CD3 bispecific antibody or antigen-binding fragment thereof may be provided together with at least one additive selected from pharmaceutically acceptable carriers, diluents, excipients, and the like.

[0207] Pharmaceutically acceptable carriers are generally used for preparing antibodies, and may be at least one selected from lactose, glucose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, etc., but are not limited thereto. In addition to the above components, the pharmaceutical composition may also include at least one selected from diluents, excipients, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc., which are generally used for preparing pharmaceutical compositions.

[0208] The pharmaceutical composition, anti-MUC1 antibody or antigen-binding fragment thereof, or anti-MUC1 / anti-CD3 bispecific antibody or antigen-binding fragment thereof can be administered orally or parenterally. In the case of parenteral administration, it can be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, intradermal administration, topical administration, intranasal administration, intrapulmonary administration, and intrarectal administration. In the case of oral administration, the protein or peptide is digested, so the oral composition should be formulated to encapsulate the active drug or protect it from degradation in the stomach. In addition, the composition can be administered with any device in which the active substance can move to the target cell.

[0209] The appropriate dosage of the pharmaceutical composition, anti-MUC1 antibody or antigen-binding fragment, or anti-MUC1 / anti-CD3 bispecific antibody or antigen-binding fragment thereof may be variously specified by factors such as the preparation method, administration method, patient age, weight, sex, disease condition, food, administration time, administration route, excretion rate and reaction sensitivity. For example, the daily dosage of the pharmaceutical composition, anti-MUC1 antibody or antigen-binding fragment, or anti-MUC1 / anti-CD3 bispecific antibody or antigen-binding fragment thereof may be 0.001 mg / kg to 1000 mg / kg, specifically, 0.01 mg / kg to 100 mg / kg, more specifically, 0.1 mg / kg to 50 mg / kg, but is not limited thereto. The daily dosage may be formulated as a preparation in a unit dosage form, or formulated by appropriate allotment, or prepared by inserting it into a multi-dose container. The term "pharmaceutically effective dose" refers to an amount that can show the desired effect of the active ingredient (i.e., anti-MUC1 antibody or antigen-binding fragment, or anti-MUC1 / anti-CD3 bispecific antibody or antigen-binding fragment thereof), in other words, the effect of preventing and / or treating cancer, and it may be variously specified by factors such as the preparation method, administration method, patient age, body weight, sex, disease condition, food, administration time, administration route, excretion rate and reactivity.

[0210] The pharmaceutical composition can be prepared in a single dose form, or by inserting it into a multi-dose container and formulating it using a pharmaceutically acceptable carrier and / or excipient. In this case, the preparation can be in the form of a solution, suspension, syrup or emulsion in an oil or aqueous medium, or can be in the form of an extract, powder, dust, granule, tablet or capsule, and can additionally contain a dispersant or stabilizer.

[0211] Furthermore, the pharmaceutical composition may be administered as a sole therapeutic agent or in combination with another therapeutic agent, and may be administered sequentially or simultaneously with conventional therapeutic agents.

[0212] On the other hand, the pharmaceutical composition comprises an antibody or an antigen-binding fragment thereof, so that it can be formulated into an immunoliposome. Liposomes comprising antibodies can be prepared according to methods well known in the art. Immunoliposomes are lipid compositions comprising phosphatidylcholine, cholesterol and polyethylene glycol-derived phosphatidylethanolamine, and can be prepared by reverse phase evaporation. For example, antibody Fab' fragments can be combined with liposomes by disulfide replacement reactions. Liposomes can also contain chemotherapeutic agents, such as doxorubicin.

[0213] The subject of administration of the pharmaceutical composition or the patient to whom the prevention and / or treatment method is administered may be a mammal, such as a primate such as a human, monkey, etc., or a rodent such as a rat, mouse, etc., but is not limited thereto, and may be a cancer patient resistant to antagonists of conventional anticancer agents, such as target cell membrane proteins (e.g., MUC1).

[0214] Methods for preparing polypeptides, recombinant vectors and antibodies

[0215] Other embodiments of the present invention provide polynucleotides encoding the above polypeptides. In a specific embodiment, the polynucleotide can encode a polypeptide comprising at least one amino acid sequence selected from SEQ ID NO: 2 to SEQ ID NO: 6, SEQ ID NO: 8 to SEQ ID NO: 15, SEQ ID NO: 17 to SEQ ID NO: 18, SEQ ID NO: 20 to SEQ ID NO: 26, SEQ ID NO: 28 to SEQ ID NO: 32, and SEQ ID NO: 34 and SEQ ID NO: 38.

[0216] In other specific embodiments, the polynucleotide may encode a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:77 to SEQ ID NO:96.

[0217] Other embodiments provide recombinant vectors comprising the polynucleotide.

[0218] Other embodiments provide recombinant cells transformed with the recombinant vector.

[0219] The term "vector" refers to a means for expressing a target gene in a host cell. For example, it includes viral vectors such as plasmid vectors, cosmid vectors and phage vectors, adenoviral vectors, retroviral vectors and adeno-associated viral vectors. The vector that can be used as a recombinant vector can be a plasmid (e.g., pSC101, pGV1106, pACYC177, ColE1, pKT230, pME290, pBR322, pUC8 / 9, pUC6, pBD9, pHC79, pIJ61, pLAFR1, pHV14, pGEX series, pET series and pUC19, etc.), a phage (e.g., λgt4λB, λ-Kalon, λΔz1 and M13, etc.) or a virus (e.g., SV40, etc.) commonly used in the art, but is not limited thereto.

[0220] In a recombinant vector, a polynucleotide can be operably linked to a promoter. The term "operably linked" refers to a functional combination between a nucleotide expression regulatory sequence (e.g., a promoter sequence) and another nucleotide sequence. A regulatory sequence can regulate the transcription and / or translation of another nucleotide sequence by being "operably linked."

[0221] Recombinant vectors can generally be constructed as vectors for cloning or for expression. The vectors used for expression can use a common vector for expressing foreign proteins in plants, animals or microorganisms. Recombinant vectors can be constructed by various methods known in the art.

[0222] Recombinant vectors can be constructed using prokaryotic cells or eukaryotic cells as hosts. For example, when the vector used is an expression vector and a prokaryotic cell is used as a host, a strong promoter capable of transcription (e.g., pLλ promoter, CMV promoter, trp promoter, lac promoter, tac promoter, T7 promoter, etc.), a ribosome binding site for initiating translation, and a transcription / translation termination sequence are generally included. When eukaryotic cells are used as hosts, the replication origins that function in eukaryotic cells included in the vector include f1 replication origin, SV40 replication origin, pMB1 replication origin, glandular replication origin, AAV replication origin, and BBV replication origin, but are not limited thereto. In addition, a promoter from a mammalian cell genome (e.g., a metallothionein promoter) or a promoter from a mammalian virus (e.g., adenovirus late promoter, vaccinia virus 7.5K promoter, SV40 promoter, cytomegalovirus promoter, and tk promoter of HSV) can be used as a transcription termination sequence, which generally has a polyadenylation sequence.

[0223] Recombinant cells can be obtained by introducing the recombinant vector into a suitable host cell. As a host cell, any host cell known in the art that can stably and continuously clone or express a recombinant vector can be used, and prokaryotic cells include, for example, Escherichia coli JM109, Escherichia coli BL21, Escherichia coli RR1, Escherichia coli LE392, Escherichia coli B, Escherichia coli X 1776, Escherichia coli W3110, Bacillus strains such as Bacillus subtilis and Bacillus thuringiensis, and Enterobacter strains such as Salmonella typhimurium, Serratia marcescens and various Pseudomonas, etc., and when it is transformed into a eukaryotic cell, yeast (Saccharomyces cerevisiae), insect cells, plant cells and animal cells can be used as host cells, such as Sp2 / 0, CHO (Chinese Hamster Ovary) K1, CHO DG44, PER.C6, W138, BHK, COS-7, 293, HepG2, Huh7, 3T3, RIN, MDCK cell lines, etc., but are not limited thereto.

[0224] The polynucleotide or the recombinant vector containing the polynucleotide is delivered (introduced) into the host cell, and a delivery method well known in the art can be used. As a delivery method, for example, when the host cell is a prokaryotic cell, a CaCl2 method or an electroporation method can be used, and when the host cell is a eukaryotic cell, microinjection, calcium phosphate precipitation, electroporation, liposome-mediated transfection and gene gun method can be used, but it is not limited thereto.

[0225] The method for screening transformed host cells can be easily carried out according to methods well known in the art, using the phenotype expressed by the selection marker. For example, when the selection marker is a specific antibiotic resistance gene, the transformant can be easily screened by culturing the transformant in a culture medium containing the antibiotic.

[0226] Other embodiments provide methods for preparing a polypeptide or an anti-MUC1 antibody or antigen-binding fragment, or an anti-MUC1 / anti-CD3 bispecific antibody or antigen-binding fragment thereof, comprising expressing a polynucleotide in a recombinant cell. Expressing the polynucleotide may include culturing the recombinant cell under conditions that allow expression of the polynucleotide contained herein. The method for preparing a polypeptide or an anti-MUC1 antibody or antigen-binding fragment, or an anti-MUC1 / anti-CD3 bispecific antibody or antigen-binding fragment thereof may also include isolating and / or purifying the polypeptide or anti-MUC1 antibody or antigen-binding fragment, or anti-MUC1 / anti-CD3 bispecific antibody or antigen-binding fragment thereof after expression or culturing.

[0227] Beneficial Effects

[0228] Anti-MUC1 antibodies and anti-MUC1 / anti-CD3 bispecific antibodies can effectively inhibit the growth of cancer cells, and therefore, they have excellent effects on preventing or treating cancer.

[0229] BRIEF DESCRIPTION OF THE DRAWINGS

[0230] Figure 1 The binding reaction of pancreatic cancer-specific MP1 monoclonal antibody to peripheral blood and normal pancreatic epithelial cells and pancreatic cancer cells is shown. (Granulocytes, lymphocytes, monocytes, normal pancreatic epithelial cells (H6C7), 5 pancreatic cancer cell lines (AsPC1, BxPC3, Capan-1, Capan-2, PANC-1))

[0231] FIG. 2A shows the results of immunohistochemistry (IHC) in pancreatic cancer tissues, and FIG. 2B shows the results of IHC in breast cancer cells. T in the figures shows the tumor site.

[0232] Figure 3 Western blot results of MP1 monoclonal antibody are shown.

[0233] Figure 4 The amino acid sequence of MUCl analyzed and identified by LC-MS / MS is shown.

[0234] Figure 5 Reactivity assay (ELISA) of MP1 monoclonal antibody against MUCl antigen is shown.

[0235] Figure 6 Reactivity assay of MP1 monoclonal antibody against MUCl antigen (IP-Western blot (IB)) is shown.

[0236] Figures 7A and 7B show the results of quantification of antigens on the surface of pancreatic cancer cell lines that respond to MP1.

[0237] FIG. 7C and FIG. 7D show the results of epitope mapping of the MP1 monoclonal antibody using the cyclic peptide array method.

[0238] Figure 8The binding reaction of MP1 humanized antibody to pancreatic cancer cells is shown, the stained cell line is Capan-2, and the heavy chain and light chain antibody gene combinations and cell binding positivity (%) are described.

[0239] Fig. 9 The structure of the LCC-type anti-MUC1 / OKT3 antibody is shown.

[0240] FIG. 10A and FIG. 10B show the results of binding of LCC-type anti-MUC1 / OKT3 antibodies to the cell surface of pancreatic cancer cells AsPC1.

[0241] Fig.11 The results of the cytotoxicity of LCC-type anti-MUC1 / OKT3 antibodies against pancreatic cancer cells Capan-2 and AsPC1 are shown.

[0242] Fig.12 The structure of the LCN-type anti-MUC1 / OKT3 antibody is shown.

[0243] Fig.13 The results of the cytotoxicity of LCN-type anti-MUC1 / OKT3 antibodies against pancreatic cancer cells Capan-1 are shown.

[0244] Fig.14 The results of the cytotoxicity of the LCN-type anti-MUC1 / OKT3 antibody against pancreatic cancer cells AsPC1 are shown.

[0245] Fig.15 The results of the cytotoxicity of the LCN-type anti-MUC1 / OKT3 antibody against pancreatic cancer cells Capan-2 and AsPC1, gastric cancer cells SNU-601, and breast cancer cells T47D are shown.

[0246] Fig.16 The present invention is a result of determining the therapeutic effect of anti-MUC1 / OKT3 antibody on cancer cells in a NOG mouse animal model in which tumors were induced by injection of pancreatic cancer cells AsPC-1.

[0247] Invention Mode

[0248] Hereinafter, the present invention will be described in more detail by the following examples. However, they are only used to illustrate the present invention, but the scope of the present invention is not limited by these examples.

[0249] Example 1: Development of MP1 monoclonal antibody

[0250] In order to develop a new antibody specific for pancreatic cancer, the following experiment was performed, and the developed antibody was partially expressed not only in pancreatic cancer but also in breast cancer and gastric cancer, and was named MP1 as a solid cancer-specific antibody.

[0251] Example 1-1. Design and screening of target sites for producing MP monoclonal antibodies

[0252] In order to develop monoclonal antibodies against specific antigens expressed in pancreatic cancer, various pancreatic cancer cell lines AsPC1, BxPC3, Capan-1, Capan-2, and PANC-1 were inoculated into mice, and then monoclonal antibodies against them were established by the cell fusion method. Thereafter, in the hybridoma screening process, antibodies that were positive for pancreatic cancer cell lines and negative for normal pancreatic cell line H6C7 and peripheral blood were screened.

[0253] Example 1-2. Hybridoma production and antibody screening

[0254] To develop monoclonal antibodies specific for pancreatic cancer, five pancreatic cancer cell lines (AsPC1, BxPC3, Capan-1, Capan-2, PANC-1) were mixed in equal amounts and immunized by injecting them into the peritoneal cavity (IP) of 6-week-old Balb / c female mice at 1×10 7, 3 weeks apart, for a total of 3 times. The spleen of the immunized mouse as described above was removed to obtain a single cell suspension, which was washed twice with RPMI1640, then mixed with 0.4% trypan blue (sigma) at 1:1 (v / v), and then the number of cells was counted using the trypan blue staining method, which measures unstained cells with a microscope. The X63 mouse myeloma cell line (ATCC CRL-1580) was used as a cell fusion partner cell and washed in the same manner as spleen cells, and then the number of cells was counted. After the myeloma cells and spleen cells were mixed, PEG (polyethylene glycol) 1500 was added to fuse the cells, and then the cells were centrifuged. The fused hybridoma cells were suspended in RPMI (20% FBS, hypoxanthine-aminopterin-thymidine) containing 1xHAT, and 150 μl of it was aliquoted into a 96-well plate, and then cultured in an incubator with 5% CO2 at 37°C. After fusion, a screening process was performed in a medium containing HAT for a period of time. When a well in which a colony was formed was observed, it was replaced with HT medium and cultured in an incubator at 37°C with 5% CO2 for 48 hours. Then, for the normal pancreatic cell line H6C7 and the five pancreatic cancer cell lines AsPC1, BxPC3, Capan-1, Capan-2, and PANC-1 used for immunization, the following fluorescent staining was performed, and they were analyzed by flow cytometry. 100ul of hybridoma culture supernatant was added to each of the prepared cells, and reacted at 4°C for 30 minutes, and then 3ml of PBS was added, and unbound antibodies were washed by centrifugation at 1700rpm for 3 minutes. In order to confirm the bound antibodies, the secondary antibody goat anti-mouse Ig-FITC (Jackson ImmunoResearch, USA) was diluted 200 times and added, and then reacted at 4°C for 15 minutes, and then washed with 3ml of PBS by the same method as above, and then measured using flow cytometry.

[0255] Examples 1-3.

[0256] To determine the extent of binding to peripheral blood, 100 μl of hybridoma supernatant was added to PBMC (peripheral blood mononuclear cells, Zenbio) and reacted at 4°C for 30 min, then 3 ml of PBS was added, and unbound antibodies were washed by centrifugation at 1700 rpm for 3 min. To determine the bound antibodies, the secondary antibody goat anti-mouse Ig-FITC (Jackson ImmunoResearch, USA) was diluted 200 times and added, then reacted at 4°C for 15 min, and washed with 3 ml of PBS as above, and then measured by flow cytometry, and the results are described ( Figure 1 ). Figure 1 The results of the reactivity of the pancreatic cancer-specific MP1 monoclonal antibody with peripheral blood and normal pancreatic epithelial cells (H6C7) and various pancreatic cancer cells are shown.

[0257] like Figure 1 As shown, a monoclonal antibody (hereinafter referred to as MP1) that is positive for various pancreatic cancer cell lines but negative for all normal pancreatic epithelial cells, H6C7 and granulocytes, lymphocytes and monocytes of peripheral blood was screened, and finally, single colonies of MP1 hybridoma cells were obtained by limiting dilution.

[0258] Example 2. Analysis of antibody expression in different cell lines

[0259] Example 2-1. Antibody expression in different cell lines

[0260] The binding of MP1 monoclonal antibody in various cancer cell lines obtained by KCLB (Korean Cell Line Bank) and ATCC (American Type Culture Collection) was determined by flow cytometry. Specifically, the cancer cell lines were cultured using RPMI1640 medium or DMEM medium according to the culture medium and method recommended by KCLB (Korean Cell Line Bank) and ATCC (American Type Culture Collection), wherein 10% heat-inactivated FBS was added at 37°C using an incubator with 5% CO2. In addition, the human pancreatic epithelial cell line H6C7 was purchased from kerafast and cultured at 37°C using Keratinocyte SFM (Invitrogen catalog number: 17005042) using an incubator with 5% CO2.

[0261] The MP1 monoclonal antibody of the present invention was added to various cultured cancer cells, respectively, and they were reacted at 4° C. for 30 minutes, then washed with PBS, FITC-labeled goat anti-mouse IgG (Jackson ImmunoResearch, USA) was added, and they were cultured at 4° C. for 15 minutes. They were washed again with PBS and then analyzed with FACS caliber (Becton Dickinson, USA) to determine the reactivity of the MP1 antibody in various solid cancer cell lines (Table 9).

[0262] As shown in Tables 9 and 10 below, it was determined that the MP1 monoclonal antibody highly binds to pancreatic cancer and some gastric cancer, breast cancer, lung cancer cell lines, as well as skin cancer and prostate cancer cell lines, while it does not bind or weakly binds to T cells and B cells including normal pancreatic epithelial cell line H6C7 and brain cancer, biliary cancer and colorectal cancer cell lines. PBMCs were negative in normal blood cells.

[0263] MP1 showed positive reactions in various pancreatic cancer cells and negative reactions in normal pancreatic epithelial cells, thus, suggesting that it can be used as a pancreatic cancer therapeutic agent.

[0264] [Table 9]

[0265]

[0266]

[0267]

[0268] [Table 10] Types of solid cancers positive for MP1 antibodies

[0269] Solid cancer types Number of positive cancer cell lines / number of stained cancer cell lines pancreas 3 / 6 Breast 5 / 11 Stomach 2 / 10 cervix 2 / 2 prostate 1 / 2 lung 4 / 11 thyroid 1 / 1 skin 1 / 1 Melanoma 1 / 3

[0270] Example 2-2. IHC (immunohistochemistry) assay

[0271] The distribution of the binding antigen of MP1 monoclonal antibody in human pancreatic cancer and breast cancer tissues was determined by immunohistochemistry (IHC).Human pancreatic cancer and breast cancer tissues were obtained from Chungbuk National University Hospital, and paraffin sections were prepared in the Department of Pathology of Chungbuk National University Hospital.

[0272] The human breast cancer tissue to be stained was fixed in formalin using conventional methods and then embedded in paraffin to make microarray sections. It was then placed on a slide to produce a single tissue slide for staining reading. Subsequently, immunohistochemical staining was performed using the MP1 antibody by the following method. The xylene was dewaxed three times for 10 minutes each time, treated with ethanol in the order of 100%, 80%, and 50%, and finally washed with distilled water. After washing with 1×TBS, the slide was placed in a 10mM citric acid (pH 6.0) antigen regeneration solution and antigen regeneration was performed in a microwave for 20 minutes. The temperature of the slide was slowly lowered using tap water and stored in 1×TBS for 10 minutes. As the primary antibody, the mouse MP1 antibody was treated to the tissue and reacted at room temperature for 1 hour, then washed three times with 1×TBS, and as the secondary antibody, the anti-mouse antibody-HRP conjugate was reacted at room temperature for 30 minutes. Wash 3 times with 1× TBS, develop with DAB for 1 minute and 30 seconds, wash 3 times with 1× TBS, counterstain for 45 seconds, and wash the slides in running tap water for 10 minutes. Dehydrate in the reverse order of the dewaxing process, seal and read under a microscope or photograph.

[0273] As shown in FIG. 2A and FIG. 2B , it was determined that the antigen recognized by the MP1 monoclonal antibody was not distributed in normal tissues and was specifically expressed on cancer tissues.

[0274] Example 3: Antigenic analysis of anti-MP1 monoclonal antibodies

[0275] Example 3-1. Confirmation of the antigen size of MP1 monoclonal antibody

[0276] Western blotting was performed to investigate the protein size of the antigen recognized by the MP1 monoclonal antibody of the present invention. Pancreatic cancer cell lines with high antigen expression for MP1 were lysed in a cell lysis solution (NP40 cell lysis buffer, Thermo Fisher Scientific) containing a protease inhibitor cocktail (Sigma, catalog number: 1136170001), and then electrophoresed in an SDS polyacrylamide gel to transfer to an Immobilon-P membrane (Millipore Corporation, Billerica, MA, USA). Afterwards, the purified MP1 monoclonal antibody was processed onto the membrane and then developed in an ECL system (GE Healthcare, Buckinghamshire, UK) to confirm the bands ( Figure 3 ). Figure 3 It could be determined that, as a result of the measurement, the size of the antigen recognized by the MP1 monoclonal antibody was close to about 300 kDa.

[0277] Example 3-2. Isolation and analysis of MP1 monoclonal antigen

[0278] Immunoprecipitation was performed to identify the antigen recognized by the MP1 monoclonal antibody of the present invention. First, 1×10 7 The cell line Capan-2, which is highly reactive to the MP1 monoclonal antibody, was lysed at 10 cells / ml, and then the cell residues were removed by centrifugation, and the supernatant was collected and used as a material for separating the antigen recognized by the MP1 antibody. The MP1 monoclonal antibody was added to Protein-G agarose gel, mixed at 4°C for 4 hours, and then washed twice with 1× PBS, and then the previously prepared Capan-2 lysate was added, mixed at 4°C for 4 hours, and then washed twice with 1× PBS. For the immune complex obtained therefrom, SDS-polyacrylamide gel electrophoresis was performed, and then the gel was stained with Coomassie Brilliant Blue G-250, and then the band of about 300 kDa, which was presumed to be an antigen against MP1, was cut and LC-MS / MS analysis was required for identification by ProteomTech. For identification, the results obtained by LC-MS / MS analysis were processed with MASCOT. When 100 protein hits obtained by the above series of analyses were expressed on the cell surface, as a result of screening by limiting the protein size to antigens of about 300 kDa, MUC1 could be screened as an antigen for anti-MP1 monoclonal antibodies ( Figure 4 The peptide sequence isolated from MP1 is QGGFLGLSNIK (SEQ ID NO: 107).

[0279] Example 3-3. Antigen identification results of MP1 monoclonal antibody verified by ELISA (enzyme-linked immunosorbent assay)

[0280] To verify the antigen identification results obtained from LC-MS / MS, the reactivity of the MUC1 monoclonal antibody to the recombinant protein MUC1 (Sino Biological, catalog number: 12123-HCCH) was determined by ELISA and Western blot assays.

[0281] 100 ng of recombinant protein MUC1 was added to the Maxisorp ELISA plate per well and reacted at 37°C for 1 hour to coat the antigen, and then 200 ul of 1x blocking solution (sigma) was added to each well and reacted at 37°C for 1 hour for blocking. MP1 monoclonal antibody and control antibody, 100 ul of PBS were added to the prepared plate respectively, which was then reacted at 37°C for 1 hour, washed with PBS and unbound antibodies were removed. Afterwards, goat anti-mouse IgG-HRP (Jackson ImmunoResearch, USA) was diluted and added, reacted for 30 minutes, then washed with PBS, and then 50 ul of TMB solution was added to each well, reacted for 10 minutes, and then 50 ul of sulfuric acid was added to stop the reaction, and the absorbance was measured at 450 nm. The MP1 monoclonal antibody against the recombinant protein MUC1 showed as follows Figure 5 Reactivity shown. Figure 5 The results were verified by ELISA that the antigen of the anti-MP1 monoclonal antibody is MUC1.

[0282] Example 3-4. Antigen identification results of MP1 monoclonal antibody verified by IP and IB

[0283] In the above experiment, it was confirmed by Western blotting that the MP1 monoclonal antibody recognized MUC1 as an antigen. As described in Example 3-2, various pancreatic cancer cell lines, BXPC3, Capan-1, Capan-2, PANC1, lysis solutions were prepared, and commercial MUC1 antibodies (BioXCell, catalog number: C595 (NCRC48)) and MP1 monoclonal antibodies were mixed with Protein-G agarose gel at 4°C for 4 hours, then washed twice with 1×PBS, and then the previously prepared lysate was added and mixed at 4°C for 4 hours, and then washed twice with 1×PBS. The immune complex thus obtained was boiled for 10 minutes, then electrophoresed in 8% SDS polyacrylamide gel, and transferred to Immobilon P membrane (Millipore Corporation, Billerica, MA, USA). Afterwards, the purified MP1 monoclonal antibody was processed onto the membrane, and then developed in an ECL system (GE Healthcare, Buckinghamshire, UK) to confirm the bands. As a result of Western blotting of the immune complex obtained by reacting the commercial MUC1 antibody and the pancreatic cancer cell line with the MP1 antibody, a band was confirmed at the position of 300 kDa, which was the same as that of the immune complex samples of Capan-2 lysate alone and MP1 and the pancreatic cancer cell line lysate. Figure 6 Western blotting confirmed that the antigen of the anti-MP1 monoclonal antibody was MUC1.

[0284] Example 4: Quantification of cell surface antigens

[0285] The quantitative flow cytometry kit QIFIKIT (Dako, catalog number: K0078) for measuring cell surface antigens was used. The antibody binding affinity (ABC) of the cell line can be calculated by calculating the mean fluorescence intensity (MFI) of the beads by comparing the graph. Figure 7A shows the results of the expression level of antigens reactive with MP1 detected on the cell surface of various pancreatic cancer cell lines (AsPC1, BxPC3, Capan-1, Capan-2, PANC1) using QIFIKIT against MP1 monoclonal antibodies.

[0286] Example 5: Epitope Mapping

[0287] The following is a partial sequence of the MUC-1 antigen used for epitope mapping (amino acid sequence 895 to 1264) (Table 11). Epitope mapping was performed using a cyclic peptide array by screening the region containing the amino acid sequence of the recombinant MUC-1 antigen for antigen identification and validation.

[0288] As can be determined in FIG. 7B , the MP1 antibody bound to the peptide comprising the PAHGVTS sequence in a dose-dependent manner, and thus, the antigen binding site, ie, epitope, of MP1 was identified as PAHGVTS (SEQ ID NO: 109).

[0289] [Table 11]

[0290]

[0291] Example 6: MP1 antibody variable region sequence and isotype analysis

[0292] Example 6-1. Isotype determination

[0293] In order to determine the isotype of the MP1 monoclonal antibody prepared in Example 1, it was analyzed using a mouse immunoglobulin isotype ELISA kit (BD Biosciences, USA). As a result, the MP1 monoclonal antibody was identified as mouse IgG2a / κ light chain.

[0294] Example 6-2. Sequence analysis of the variable region of MP1 antibody

[0295] Use Mouse Ig-Primer Set (Merck Millipore, catalog number: 69831) to clone MP1 antibody gene. Use Mouse Ig-Primer Set to carry out PCR to RNA isolated from MP1 hybridoma, and insert it into pGEM-T vector (Promega, catalog number: A3600), then confirm DNA base sequence by sequencing, confirm mouse antibody gene by IMGT site (www.imgt.org). Table 12 shows the analysis sequence of MP1 antibody heavy chain and light chain variable region. The bold underlined part in the amino acid sequence described below represents complementary determining region. In the following table 12, sequence position is written according to Kabat numbering system.

[0296] [Table 12]

[0297]

[0298]

[0299] Example 7: Development of MP1 humanized antibody

[0300] Before preparing bispecific antibodies, when the mouse antibody is administered to the human body, a humanized antibody in which the MP1 variable region and other parts are replaced by human Fc is prepared to reduce the immunogenicity shown by the human anti-mouse antibody (HAMA) reaction and ensure that the antibody has high drugability. It was determined that the screened humanized antibodies had similar antigenic specificity and affinity to the original mouse MP1 antibody.

[0301] Example 7.1 Screening of recombinant antibody sequences by computer humanization

[0302] The CDR region sequences of the heavy chain and light chain of the mouse antibody MP1 (heavy chain amino acid sequence: SEQ ID NO: 77; light chain amino acid sequence: SEQ ID NO: 87) are VH-CDR1: SEQ ID NO: 2 (DYWMN); VH-CDR2: SEQ ID NO: 8 (QIRNKPYNYETYYSNSVKG); VH-CDR3: SEQ ID NO: 17 (AMITSDGYAMDY); VL-CDR1: SEQ ID NO: 20 (KSSQSLLLSSNQKNYLA); VL-CDR2: SEQ ID NO: 28 (WASTRES); VL-CDR3: SEQ ID NO: 34 (QQCFSYPLT). Based on the germline sequence encoding the human antibody gene, the sequence region of the framework region was recombined by computer methods to screen for humanized antibodies having the same or superior antigen binding affinity while maintaining the heavy chain and light chain amino acid sequences of the mouse antibody MP1 as similarly as possible. Since each sequence of the heavy chain and light chain has the highest similarity with the mouse antibody MP1, the human antibody germline genes used as the framework of the humanized recombinant antibody sequence are shown in Table 13 below.

[0303] The amino acid sequences of the heavy chain variable region amino acid sequence and the light chain variable region amino acid sequence of the selected humanized antibodies are shown in the following Table 14. The bold underlined portion in the amino acid sequence described below represents a complementarity determining region.

[0304] [Table 13]

[0305]

[0306] [Table 14]

[0307]

[0308]

[0309]

[0310] Example 7.2 Expression and analysis of humanized recombinant antibodies

[0311] The amino acid sequences corresponding to the expression genes of 9 heavy chains (including VH1 to VH9) and 9 light chains (VL1 to VL9) in Table 14 above were codon optimized to synthesize DNA sequences, and the synthesized DNA was connected to human Fc region genes (human IgG1 Fc genes of heavy chains, human Igκ constant genes of light chains) by overlapping PCR to clone them into the pcDNA3.4 vector included in the ExpiCHO-S expression system kit (Gibco, the United States). The plasmids expressing the light and heavy chains of the humanized MP1 antibodies manufactured were transfected into the ExpiCHO-S cell line using the ExpiCHO-S expression system kit (Invitrogen / Life technologies) to produce transient expression on a 48-well scale.

[0312] Using the culture fluid of the expressed humanized antibody, 1) the presence or absence of cell surface binding was confirmed by staining the pancreatic cancer cell line Capan-2, and 2) the presence or absence of humanized antibody expression was confirmed by anti-human Ig antibody sandwich ELISA. Among a total of 81 heavy chain and light chain combinations (i.e., antibody combinations comprising heavy chains and light chains, the heavy chain comprising any one of the heavy chain variable regions selected from the 9 heavy chain variable regions shown in Table 14, and the light chain comprising any one of the light chain variable regions selected from the 9 light chain variable regions shown in Table 14), it was determined that the humanized antibody combination showed a similar pattern of cell surface binding to the original mouse antibody or chimeric antibody, and based on the results of the sandwich ELISA that determined the expression level of the transiently expressed humanized antibody, it was determined that the antibody was expressed as a whole (Table 15).

[0313] [Table 15]

[0314]

[0315] In the above Table 15, cell surface binding (%) indicates the positive rate % of antibody binding to the cell surface compared with the negative control group, and expression (sandwich ELISA) is the 450 nm OD value of sandwich ELISA.

[0316] Of the 81 antibodies prepared in Table 15 above, 20 antibodies with high Capan-2 cell surface binding (%) are shown. As can be determined in Table 12, VH8 / VL3 (an antibody comprising a heavy chain containing the heavy chain variable region VH8 of Table 14 and a light chain containing the light chain variable region VL3 of Table 14; the same below), VH1 / VL5, VH4 / VL4, VH4 / VL5, VH1 / VL4, VH8 / VL4, VH1 / VL2, VH7 / VL4, VH7 / VL3, VH8 / VL2, VH4 / VL8 and VH4 / VL7 antibodies showed excellent Capan-2 cell surface binding.

[0317] The antibody genes of the humanized antibody heavy chain and light chain combination with high positive in the initial transient expression were expanded from 48 wells to 6 wells for transient expression again, and then the binding ability to the Capan-2 pancreatic cancer cell line was confirmed again ( Figure 8 ).

[0318] like Figure 8 As shown, among the VH1 / VL5, VH4 / VL4, VH4 / VL5, VH1 / VL4, VH1 / VL2 and VH7 / VL4 antibodies, Capan-2 cell surface binding was excellent.

[0319] Example 8. In vitro efficacy: T cell binding bispecific antibody / format optimization

[0320] Example 8-1. Expression of T cell binding bispecific antibodies using humanized MP1 antibody

[0321] Among various bispecific antibody formats, a tetravalent bispecific antibody was expressed, which exhibited T cell activity and high anti-cancer function while having an Fc region, thereby maintaining a half-life close to that of the original antibody. The anti-CD3 antibody for T cell activity uses the humanized antibody variable region of the OKT3 antibody exhibiting T cell activity. The sequence of the humanized OKT3 antibody is cited and used from U.S. Patent 20090202532 A1, which is a sequence corresponding to SEQ ID NO: 103, SEQ ID NO: 105, and SEQ ID NO: 106 in Table 13 below. SEQ ID NO: 103 is the amino acid sequence of the humanized OKT3 antibody heavy chain variable region, SEQ ID NO: 104 is the amino acid sequence of the humanized OKT3 antibody light chain variable region, and SEQ ID NO: 105 represents the amino acid sequence of the humanized OKT3 antibody scFv antibody. The humanized OKT3 antibody consists of a single-chain Fv (scFv) connected between the heavy chain variable region sequence and the light chain variable region sequence with a [GGGS]n=5 linker, and is connected to the light chain N-terminus (LCN type) or C-terminus (LCC type) of the humanized MP1 antibody with a [GGGS]n=3 linker.

[0322] For humanized OKT3 scFv, glycine at position 44 of the heavy chain variable region and glycine at position 100 of the light chain variable region were replaced with cysteine ​​in order to increase stability by inducing interdomain disulfide bonds (Protein Engineering, Design & Selection vol. 25 no. 7 pp. 321-329, 2012).

[0323] In order to express it as a bispecific antibody, the humanized MP1 heavy chain gene (gene encoding any heavy chain of VH1 to VH9 in Table 11 above) plasmid and LCN or LCC type humanized MP1 light chain-OKT3scFv gene (gene encoding a light chain sequence containing the light chain complementary determining region of VL4 or VL5 in Table 11 above-OKT3scFv gene) plasmid were transfected into ExpiCHO-S cells at a ratio of 1:1.7. After 7 or 10 days, the transfected bispecific antibody culture fluid was used for antibody expression (sandwich ELISA using anti-human Ig), cell line binding (cell surface staining and flow cytometry analysis) and cytotoxicity assays, and the activity was purified by protein A affinity chromatography to obtain a determined bispecific antibody culture fluid.

[0324] The sequences of the anti-MUC1 / anti-CD3 bispecific antibodies prepared above (light chain sequence of anti-MU1 antibody and scFv sequence of anti-CD3 antibody) are shown in the following Table 13. The form in which the anti-CD3 antibody (OFT3-scFv) is bound to the C-terminus of the light chain of the anti-MUC1 antibody is represented as LCC, and the form in which it is bound to the N-terminus of the light chain is represented as LCN.

[0325] In the following Table 16, the LCC-type anti-MUC1 / anti-CD3 bispecific antibodies (see Fig. 9 ), LCC type humanized MP1 light chain #4-OKT3scFv represents the light chain sequence (SEQ ID NO: 112) of the anti-MUC1 / anti-CD3 bispecific antibody, wherein the humanized OKT3scFv antibody (SEQ ID NO: 106) is bound to the C-terminus of a light chain sequence (SEQ ID NO: 110) comprising a light chain variable region (SEQ ID NO: 91) of light chain No. 4 (VL4) of Table 14. LCC type humanized MP1 light chain #5-OKT3scFv represents the light chain sequence (SEQ ID NO: 113) of the anti-MUC1 / anti-CD3 bispecific antibody, wherein the humanized OKT3scFv antibody (SEQ ID NO: 106) is bound to the C-terminus of a light chain sequence (SEQ ID NO: 111) comprising a light chain variable region (SEQ ID NO: 92) of light chain No. 5 (VL5) of Table 14.

[0326] In the following Table 16, LCN type anti-MUC1 / anti-CD3 bispecific antibodies (see Fig.12), LCN type humanized MP1 light chain #4-OKT3scFv represents the light chain sequence (SEQ ID NO: 114) of the anti-MUC1 / anti-CD3 bispecific antibody, wherein the humanized OKT3scFv antibody (SEQ ID NO: 106) is bound to the N-terminus of the light chain sequence (SEQ ID NO: 110) comprising the light chain variable region (SEQ ID NO: 91) of light chain No. 4 (VL4) of Table 14. LCN type humanized MP1 light chain #4-OKT3scFv represents the light chain sequence (SEQ ID NO: 115) of the anti-MUC1 / anti-CD3 bispecific antibody, wherein the OKT3scFv antibody (SEQ ID NO: 106) is bound to the C-terminus of the light chain sequence (SEQ ID NO: 111) comprising the light chain variable region (SEQ ID NO: 92) of light chain No. 5 (VL5) of Table 14.

[0327] Among the 4 light chain sequences of the anti-MUC1 / anti-CD3 bispecific antibody, the light chains of the anti-MUC1 antibody and the humanized OKT3scFv antibody were linked with a [GGGS] n = 3 linker. For the heavy chain of the anti-MUC1 / anti-CD3 bispecific antibody, the heavy chain sequences comprising the heavy chain variable regions of heavy chain No. 1 to heavy chain No. 9 in Table 14 (SEQ ID NO: 78 to SEQ ID NO: 86) were used.

[0328] [Table 16]

[0329]

[0330]

[0331]

[0332] Example 8-2. Functional analysis of LCC-type humanized MP1 bispecific antibody

[0333] For the LCC-type anti-MUC1 / anti-CD3 bispecific antibodies prepared in Example 8-1, surface binding affinity and cytotoxicity were determined for MUC1 antigen-positive AsPC1 pancreatic cancer cells. Anti-MUC1 / anti-CD3 bispecific antibodies were expressed at the protein level (Table 17) by sandwich ELISA using anti-human Ig / anti-human Ig-HRP, and these bispecific antibodies were determined to bind to MUC1 antigen-positive AsPC1 pancreatic cancer cells by cell surface staining and flow cytometry ( FIG. 10 ).

[0334] As a control group, an anti-mesothelin / OKTscFv humanized bispecific antibody (MSTN-OKT3) was used. MSTN-OKT3 is a LCC type bispecific antibody in which the sequence of the h7D9.v3 antibody described in the International Publication (WO 2012 / 087962) was used to bind the humanized OKT3 scFv sequence (SEQ ID NO: 106) to the C-terminus of the light chain of the h7D9.v3 antibody.

[0335] [Table 17]

[0336] Antibody Express Antibody Express VH1 / VL5 2.4501 VH1 / VL4 1.8550 VH2 / VL5 1.4389 VH2 / VL4 1.2238 VH3 / VL5 1.5525 VH3 / VL4 1.2721 VH4 / VL5 2.2260 VH4 / VL4 1.5691 VH5 / VL5 1.2155 VH5 / VL4 0.7501 VH6 / VL5 1.3825 VH6 / VL4 0.9205 VH7 / VL5 2.1425 VH7 / VL4 1.5371 VH8 / VL5 1.7722 VH8 / VL4 1.6626 VH9 / VL5 1.2984 VH9 / VL4 1.0687

[0337] In Table 17 above, expression (sandwich ELISA) is the 450nm OD value of sandwich ELISA. In one embodiment, the antibody "VH1 / VL5" refers to an anti-MUC1 / anti-CD3 bispecific antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises the heavy chain variable region (SEQ ID NO: 78) of heavy chain No. 1 (VH1) in Table 14, and the light chain (SEQ ID NO: 113) wherein the humanized OKT3 scFv antibody (SEQ ID NO: 106) is bound to the C-terminus of the light chain variable region (SEQ ID NO: 92) of light chain No. 5 (VL5) in Table 14.

[0338] Although in Table 17 above, the antibodies were expressed, they were negative in the flow cytometer of Figure 10 because the affinity of the original antibody was lost during the humanized antibody binding process. In addition, as can be determined in Figure 10, among the bispecific antibody combinations, the bispecific antibody combination that simultaneously expresses the No. 4 light chain-OKT3 scFv antibody (i.e., a bispecific antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises any one of the heavy chain variable regions of the No. 1 heavy chain to the No. 9 heavy chain in Table 14, and the humanized OKT3 scFv antibody is bound to the C-terminus of the light chain variable region of the No. 4 light chain) showed all cell surface binding, but among the bispecific antibody combinations that together express the No. 5 light chain-OKT3 scFv antibody, only the combinations of the No. 1 heavy chain / No. 5 light chain, the No. 2 heavy chain / No. 5 light chain, and the No. 7 heavy chain / No. 5 light chain showed cell surface binding.

[0339] For the expressed bispecific antibodies, cytotoxicity assays were performed using Capan-2 and AsPC-1 cell lines as target cells and human T cells as effector cells. The ratio of target cells to effector cells was set at 1:10, and the input amount of bispecific antibodies was the same, 1 ug / ml. After 48 hours, the death of target cells was measured using EZ-Cytox (DogenBio, catalog number: EZ-1000), and the cytotoxicity % was calculated using the following formula, Fig.11 shown.

[0340] % cytotoxicity = (1-(measurement value of antibody administration well / measurement value of target cell and effector cell well)) x 100

[0341] As in Fig.11 As can be determined in Example 8-2, the effect was not well shown because the LCC-type anti-MUC1 / anti-CD3 bispecific antibody prepared in Example 8-2 had a lower effect than the control antibody (MSTN-OKT3), and the cytotoxicity was less than 30%.

[0342] Example 8-3. Functional analysis of LCN-type humanized MP1 bispecific antibody (1)

[0343] The surface binding ability and cytotoxicity of the LCN-type anti-MUC1 / anti-CD3 bispecific antibody prepared in Example 8-1 were measured on MUC1 antigen-positive pancreatic cancer cells Capan-1 and AsPC1.

[0344] The expression of the LCN-type anti-MUC1 / anti-CD3 bispecific antibodies shown in Table 16 above at the protein level was determined by sandwich ELISA using anti-human Ig / anti-human Ig-HRP, and the binding of these bispecific antibodies to MUC1 antigen-positive pancreatic cancer cells Capan-1 and AsPC1 was determined by staining and flow cytometry.

[0345] Such results as Fig.13 and Fig.14 As a control group, an anti-MUC1 / anti-CD3 bispecific antibody (chi / 4) comprising a heavy chain comprising the heavy chain variable region (SEQ ID NO: 77) of the mouse MUC1 antibody in Table 12 and a light chain in which the humanized OKT3 scFv antibody is bound to the N-terminus of a light chain sequence (SEQ ID NO: 110) comprising the light chain variable region (SEQ ID NO: 91) of light chain No. 4 (VL4) in Table 14 was used.

[0346] like Fig.13 and Fig.14As shown, it was determined that the anti-MUC1 / anti-CD3 bispecific antibody of the heavy chain No. 1 / light chain combination ("1 / 4", i.e., an anti-MUC1 / anti-CD3 bispecific antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises the heavy chain variable region (SEQ ID NO: 78) of the heavy chain No. 1 (VH1) in Table 14, and a light chain (SEQ ID NO: 114), and the light chain (SEQ ID NO: 114) in which the humanized OKT3 scFv antibody (SEQ ID NO: 106) is bound to the N-terminus of the light chain variable region (SEQ ID NO: 91) of the light chain No. 4 (VL4) in Table 14; the same below), compared with the control group, the heavy chain No. 4 / light chain No. 4 ("4 / 4") and the heavy chain No. 7 / light chain No. 4 ("7 / 4") had excellent toxic effects on cancer cells.

[0347] This result indicates that the LCN-type bispecific antibody (Example 8-3) can bind by maintaining a closer micro-distance between cancer cells and T cells, which is easier to exhibit cytotoxicity than the LCC-type bispecific antibody (Example 8-2), and through this, it can exhibit higher cytotoxicity.

[0348] Example 8-4. Functional analysis of LCN-type humanized MP1 bispecific antibody (2)

[0349] For the LCN-type anti-MUC1 / anti-CD3 bispecific antibody prepared in Example 8-1, cytotoxicity assays were performed on AsPC-1 and Capan-2 (pancreatic cancer cell lines), SNU-601 (gastric cancer cell line), and T47D (breast cancer cell line) cell lines that are positive for the MUC1 antigen, and the in vitro cytotoxic effects were determined. The results are shown in Fig.15 middle.

[0350] For the anti-MUC1 / anti-CD3 bispecific antibody, an anti-MUC1 / anti-CD3 bispecific antibody with a higher humanization ratio of heavy chain No. 1 / light chain No. 5 was used, that is, an anti-MUC1 / anti-CD3 bispecific antibody comprising a heavy chain variable region (SEQ ID NO: 78) of heavy chain No. 1 (VH1) in Table 14 and a humanized OKT3 scFv antibody (SEQ ID NO: 106) connected to the N-terminus of the light chain variable region (SEQ ID NO: 92) of light chain No. 5 (VL5) in Table 14.

[0351] like Fig.15 As shown, it was determined that the cytotoxic effect against cancer cells was proportional to the concentration of the administered LCN-type anti-MUC1 / anti-CD3 bispecific antibody.

[0352] Example 9: Evaluation of the therapeutic effect of humanized bispecific antibodies using a pancreatic cancer mouse experimental model

[0353] In order to determine the in vivo immune anticancer effect of the anti-MUC1 / anti-CD3 bispecific antibody, the NOG mouse animal model transplanted with the human pancreatic cancer cell line AsPC-1 was evaluated to see whether the size of the tumor was reduced by administering the anti-MUC1 / anti-CD3 bispecific antibody. For the anti-MUC1 / anti-CD3 bispecific antibody, the same antibody as that used in Example 8-4 (LCN type No. 1 heavy chain / No. 5 light chain combination anti-MUC1 / anti-CD3 bispecific antibody) was used.

[0354] Mouse model preparation

[0355] In order to evaluate the anticancer effect of antibodies using a large number of human immune cells, NOG mice lacking T cell, B cell, NK cell, macrophage, and dendritic cell functions (NOD / Shi-scid, IL-2RγKO mice, Koatech) were used as mice. 6 The pancreatic cancer cell line AsPC-1 was injected subcutaneously (intraperitoneally) into the flank of 8-week-old NOG mice. Five mice in each group were selected 1 to 2 weeks later to form a 100 mm 3 Up to 150mm 3 Mice with tumor volumes were selected and used for experiments.

[0356] Human PBMC preparation

[0357] 10 days before the injection of the antibody, RPMI1640 (GeneDireX, catalog number: CC112-0500) containing 10% FBS and cryopreserved human peripheral blood mononuclear cells (PBMC) purchased from Zenbio were thawed, and then on the first day, 250ng / ml of IFN-r (jwcreagene, catalog number: HIFNG-100) was treated, and on the second day, 30ng / ml of IL-2 (jwcreagene, JW-H031-0100) and 50ng / ml of OKT3 antibody (Miltenyi Biotec, catalog number: 130-093-387) were added, and then placed for 5 days. Thereafter, 30ng / ml of IL-2 and 50ng / ml of IFN-r were cultured in RPMI1640 medium (wherein 10% FBS was added from the 6th to the 16th day of culture) to expand the number of PBMCs.

[0358] Evaluation of the anticancer effect of humanized MP1 bispecific antibody

[0359] The tumor-bearing NOG mice were divided into 6 groups. On day 0, 200 μl of PBS was intraperitoneally injected into one group, and 5×10 6PBMCs with 10 cells were injected intraperitoneally into each of the five groups of mice (in other words, the suspension was prepared with 1× PBS so that it was 5×10 6 Then, the anti-MUC1 / anti-CD3 bispecific antibody and PBMC were injected into 4 groups of mice at 1 mg / kg and 3 mg / kg, respectively, and the size of the subcutaneously injected cancer cells was observed and measured after a total of 4 intravenous (IV) injections on days 3, 7, 10, and 14.

[0360] Fig.16 The results of in vivo anticancer efficacy in a mouse pancreatic cancer animal model using an anti-MUC1 / anti-CD3 bispecific antibody injected with PBMC under humanized conditions are shown. Compared with the group administered with PBMC only (control-PBMC), the antibody-administered groups (MP1-1 mg / kg and MP1-3 mg / kg) showed a higher anticancer effect (tumor growth inhibition; TGI). Based on the above, those skilled in the art to which the present invention belongs will understand that the present invention can be implemented in other specific forms without changing its technical spirit or basic characteristics.

[0361] In this regard, the above embodiments should be understood to be illustrative in all aspects, rather than non-restrictive. The scope of the present invention should be interpreted as all changes or modified forms derived from the meaning and scope of the claims described below, and its equivalent concepts are also included in the protection scope of the present invention.

Claims

1. An anti-MUC1 (mucin-1) antibody or an antigen-binding fragment thereof, comprising a polypeptide having the amino acid sequence of SEQ ID NO: 1 (VH-CDR1), a polypeptide having the amino acid sequence of SEQ ID NO: 7 (VH-CDR2), a polypeptide having the amino acid sequence of SEQ ID NO: 16 (VH-CDR3), a polypeptide having the amino acid sequence of SEQ ID NO: 19 (VL-CDR1), a polypeptide having the amino acid sequence of SEQ ID NO: 27 (VL-CDR2), and A polypeptide having the amino acid sequence of SEQ ID NO: 33 (VL-CDR3).

2. The anti-MUC1 antibody or antigen-binding fragment thereof according to claim 1, comprising a polypeptide (VH-CDR1) having an amino acid sequence selected from the group consisting of SEQ ID NO: 2 to SEQ ID NO: 6, a polypeptide (VH-CDR2) having an amino acid sequence selected from the group consisting of SEQ ID NO: 8 to SEQ ID NO: 15, a polypeptide (VH-CDR3) having an amino acid sequence selected from the group consisting of SEQ ID NO: 17 to SEQ ID NO: 18, a polypeptide (VL-CDR1) having an amino acid sequence selected from the group consisting of SEQ ID NO: 20 to SEQ ID NO: 26, a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 28 to SEQ ID NO: 32 (VL-CDR2), and A polypeptide (VL-CDR3) having an amino acid sequence selected from the group consisting of SEQ ID NO: 34 to SEQ ID NO:

38.

3. The anti-MUC1 antibody or antigen-binding fragment thereof according to claim 1, comprising a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 77 to SEQ ID NO: 86; and A light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 87 to SEQ ID NO:

96. 4 . The anti-MUC1 antibody or antigen-binding fragment thereof according to claim 1 , wherein the anti-MUC1 antibody or antigen-binding fragment has an activity of inducing apoptosis of cancer cells expressing MUC1.

5. The anti-MUC1 antibody or antigen-binding fragment thereof of claim 1, wherein the anti-MUC1 antibody is a monoclonal antibody. 6 . The anti-MUC1 antibody or antigen-binding fragment thereof according to claim 1 , which specifically recognizes a peptide comprising the amino acid sequence of SEQ ID NO:

109.

7. The anti-MUC1 antibody biological fragment or antigen-binding fragment thereof according to claim 1, wherein the antigen-binding fragment is selected from scFv, (scFv)2, Fab, Fab' and F(ab')2 of anti-MUC1 antibody.

8. The anti-MUC1 antibody or antigen-binding fragment thereof according to claim 1, wherein the anti-MUC1 antibody is a murine antibody, a human-mouse chimeric antibody, a humanized antibody or a human antibody.

9. A bispecific antibody comprising the anti-MUC1 antibody or antigen-binding fragment thereof of any one of claims 1 to 8, and at least one antigen-binding site specific for a T cell activation antigen.

10. The bispecific antibody of claim 9, wherein the T cell activation antigen is a CD3 T cell co-receptor (CD3) antigen.

11. The bispecific antibody according to claim 10, wherein the bispecific antibody comprises an anti-CD3 antibody or an antigen-binding fragment thereof, wherein the antigen-binding fragment comprises an antigen-binding site for a CD3 antigen, The anti-CD3 antibody or antigen-binding fragment thereof is OKT3 antibody or an antigen-binding fragment thereof, UCHT-1 antibody or an antigen-binding fragment thereof, or SP34 antibody or an antigen-binding fragment thereof. 12 . The bispecific antibody of claim 11 , wherein the anti-CD3 antibody or antigen-binding fragment thereof is linked to the C-terminus or N-terminus of the anti-MUC1 antibody or antigen-binding fragment thereof.

13. The bispecific antibody according to claim 11, wherein the antigen-binding fragment of the anti-CD3 antibody is selected from the group consisting of scFv, (scFv)2, Fab, Fab' and F(ab')2 of the anti-CD3 antibody.

14. The bispecific antibody of claim 11, wherein the anti-CD3 antibody or antigen-binding fragment thereof comprises a polypeptide having the amino acid sequence of SEQ ID NO: 97 (VH-CDR1), a polypeptide having the amino acid sequence of SEQ ID NO: 98 (VH-CDR2), a polypeptide having the amino acid sequence of SEQ ID NO: 99 (VH-CDR3), a polypeptide having the amino acid sequence of SEQ ID NO: 100 (VL-CDR1), A polypeptide having the amino acid sequence of SEQ ID NO: 101 (VL-CDR2), and A polypeptide having the amino acid sequence of SEQ ID NO: 102 (VL-CDR3). 15 . A pharmaceutical composition for preventing or treating cancer, comprising the anti-MUC1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 8, or the bispecific antibody according to any one of claims 9 to 14.

16. The pharmaceutical composition for preventing or treating cancer according to claim 15, wherein the cancer is at least one cancer selected from blood cancer, bone marrow cancer, thyroid cancer, cervical cancer, skin cancer, melanoma, breast cancer, colorectal cancer, lung cancer, gastric cancer, prostate cancer and pancreatic cancer. 17 . A polynucleotide encoding the anti-MUC1 antibody or antigen-binding fragment thereof according to any one of claims 1 to 8 , or the bispecific antibody according to any one of claims 9 to 14 . A recombinant vector comprising the polynucleotide according to claim 17 . A recombinant cell comprising the recombinant vector according to claim 18 .